report banner

News in English

Enter any phrase or word you would like to search for and click .
PostNews: Press Release
ARM-ATMP-banner-web

PHI Strengthens Commitment to Regenerative Medicine through ARM and ATMP Sweden Membership

PHI becomes a member of the leading international advocacy organization Alliance for Regenerative Medicine (ARM) as well as the national ATMP Sweden network to advocate for QPI technology for standard cell quality control in regenerative medicine.
Learn more …
PostNews
BioStock: PHI charts a bold course to impact regenerative medicine

BioStock: PHI charts a bold course to impact regenerative medicine

BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.
Learn more …
PostNews
righst issue of units 2022 banner

BioStock: The five best life science stocks of the first half-year

PHI is proud to be highlighted as one of the top 5 best-performing Swedish life science stocks in the first half of 2023.
Learn more …
PostNews: Press Release
Artistic image of molecularly imprinted polymers (MIP).

European Patent Office intends to grant PHI patent on synthetic antibodies

PHI AB announces today that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies.
Learn more …
PostNews
PHI-worldtour-1024x576

BioStock: PHI’s CEO reflects on global roadshow success

BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.
Learn more …
PostNews: Interim Report
Well A2-1 2

Interim Report 4 2022/23

Sales continue to grow, and the year ended up with the highest turnover for a year in PHI, so far.
Learn more …
1…34567…32

Latest Commentaries

OvarianCancer

Fighting cancer with nanoparticles

Using HoloMonitor, scientists at Northeastern University have shown that paclitaxel-resistant ovarian cancer cells stopped multiplying by cell division when treated with nanoparticles. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.
Angiogenesis

No Blood, No Tumor

Scientists at Boston Children’s Hospital have used HoloMonitor to study living bone cancer cells. By studying their dynamics, they have successfully for the first time distinguished aggressive bone cancer cells that promote blood vessel formation from the harmless counterparts that do not promote blood vessel formation.

Big Data, Fewer Cells

Scientists at Holographic Imaging Cytometry Program of Excellence at Northeastern University have developed a method to compare time series data of drug treated cells with untreated cells.
See All Commentaries

Latest Blogs

Publication-highlight

2022 publication highlights

In 2022, researchers around the world published 34 publications featuring HoloMonitor. We are thrilled to see how HoloMonitor helps scientists around the world explore new areas of study and address questions from cancer research to neuroscience.
Learn more …
User-spotlight-Tianyan-Wang-banner_website-blog

HoloMonitor user Spotlight: Tianyan Wang

Tianyan talks about how digital holographic cytometry (DHC) and HoloMonitor data have been key in his Ph.D. thesis: Utility of Novel Drug Targets for Treatment of Metastatic Cancer.
Learn more …
User-spotlight-Francesco-Pasqualini-banner_web

HoloMonitor User Spotlight: Francesco Pasqualini

Francesco Pasqualini, Associate Professor at University Pavia, tells how he applies HoloMonitor to see how ECM affects cells over a long time.
Learn more …
See All Blogs